That higher concentrations of CC-96191 exert cytotoxic effects on CD33+ AML cells that are similar in magnitude to those induced by a potent CD33/CD3 yet result in lower levels of cytokines, suggests the possibility of improved safety with the TriNKET relative to a T cell-engaging BsAb. This evidence concerns the gene CD33 and acute myeloid leukemia.